Kymera Therapeutics Inc. debuted on NASDAQ Friday by pricing its upsized IPO of 8.68 million common shares at $20 each as it eyes gross proceeds of $173.3 million. By the end of the day, Kymera stock (NASDAQ:KYMR) had soared 66.3%, with shares closing at $33.26 each.

C4 Therapeutics Inc., a company focused on destroying disease-causing proteins via degradation, has closed a $170 million financing intended to help move four cancer candidates into the clinic by the end of 2022.